Genetic variants in the NF-κB signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patientsNF-κB 신호 전달 경로(NFKB1, NFKBIA, NFKBIZ)의 유전적 변이와 COVID-19 환자의 중대한 결과 위험Article Published on 2022-08-012022-09-11 Journal: Human immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Cohort component Control COVID-19 COVID-19 patient Critical D-dimer value Deceased explain form Gene polymorphisms genetic association Genetic variation Genotype healthy Homozygosis hyperinflammatory state ICU ICU admission implicated Inflammation insertion lower expression mice Mortality NF-κB NF-κB signaling NF-κB signaling pathway NFkB1 NFKBIA NFKBIZ NFKBIZ. outcome pathway Patient patients populations predisposition RATs Respiratory Support risk risk of death SARS-COV-2 infection Sepsis severe COVID-19 severe forms of COVID-19 significant effect Spanish patient Survivors the patient total blood transcript variant variants viral disease was increased [DOI] 10.1016/j.humimm.2022.06.002 PMC 바로가기 [Article Type] Article
Culling of Urban Norway Rats and Carriage of Bartonella spp. Bacteria, Vancouver, British Columbia, CanadaArticle Published on 2022-08-012023-06-14 Journal: Emerging Infectious Diseases [Category] Fulltext, 조류인플루엔자, [키워드] Bacteria Bartonella Canada Ecology pest control RATs Siphonaptera vector-borne infections zoonoses [DOI] 10.3201/eid2808.211164 PMC 바로가기
Seroprevalence of Anti-Hepatitis E Virus Antibodies among Patients from a Tertiary Hospital from Northeast Romania루마니아 북동부 지역의 3차 병원 환자에서 E형 간염 바이러스 항체의 혈청 유병률Article Published on 2022-07-292022-09-11 Journal: Medicina [Category] E형 간염, MERS, 진단, 치료기술, [키워드] antibodies antibody being clinic clinical Consumption Contact contact with COVID-19 criterion cross-sectional cross-sectional study disease Endemic endemic region Enrollment Europe European Evidence evidence of Gender groups Hepatitis hepatitis E hepatitis E virus IgG antibodies Infection Infectious disease Infectious diseases material median age no significant difference no significant differences objective pathogen Patient patients PIGS positive poultry Prevalence RATs Result risk factor Romania Seroprevalence serum silent subclinical infection Tertiary Transmission transmitted virus water zoonotic transmission [DOI] 10.3390/medicina58081020 PMC 바로가기 [Article Type] Article
Monitoring Urban Zoonotic Virus Activity: Are City Rats a Promising Surveillance Tool for Emerging Viruses?Article Published on 2022-07-112023-06-22 Journal: Viruses [Category] 조류인플루엔자, [키워드] Disease surveillance Emerging infectious diseases environmental monitoring RATs urban viral zoonoses [DOI] 10.3390/v14071516 PMC 바로가기
Clinical Performance of Rapid and Point-of-Care Antigen Tests for SARS-CoV-2 Variants of Concern: A Living Systematic Review and Meta-AnalysisSARS-CoV-2 우려 변종에 대한 신속한 현장 진료 항원 검사의 임상 성능: 살아있는 체계적인 검토 및 메타 분석Review Published on 2022-07-062022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] 95% CI 95% confidence interval Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antigen article calculate caused CENTRAL Chain Reaction clinical conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients Diagnosis diagnostic diagnostic value dropped facilitate management Meta-analysis pandemic performance polymerase chain reaction random effect Rapid rapid antigen test Rapid antigen tests RAT RATs real-time reverse transcription-polymerase chain reaction reference test review SARS-CoV-2 sensitivities sensitivity Sensitivity and specificity Seven severe acute respiratory syndrome Coronavirus Test utility variant variants were assessed [DOI] 10.3390/v14071479 PMC 바로가기 [Article Type] Review
Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats임신한 쥐에서 항바이러스성 렘데시비르와 주요 대사산물인 GS-441524의 생체변환 및 태반 전이Article Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] 치료제, [키워드] amniotic Amniotic fluid Anti-viral approved AUC Biotransformation Blood Blood-placental barrier C max coronavirus disease Coronavirus disease 2019 COVID-19 cross during pregnancy evaluated fetus GS-441524 Hypothesis Liquid chromatography mass spectrometry maternal blood metabolite Microdialysis MONITOR mother multisite nucleoside parameter pharmacokinetic pharmacokinetics Placenta placental barrier predominant Pregnancy pregnant RATs Remdesivir Science shown Taiwan Tandem mass spectrometry technology tissues transfer treat Treatment UHPLC was used while [DOI] 10.1016/j.ebiom.2022.104095 PMC 바로가기 [Article Type] Article
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 우려 변종에 대한 CpG-보강 S-2P 소단위 백신의 중화 능력 평가Article Published on 2022-06-102022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 진단, [키워드] Ability acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against Alpha Alpha variant aluminum aluminum hydroxide antibody Antigen Beta Beta variant beta variants breath clinical trial coated with concern coronavirus coronavirus 2 COVID-19 CpG D614G demonstrated dose effective Effectiveness elicit elicited Evaluating High dose Human humans hydroxide immune response immunization immunized immunogenicity medium neutralization neutralization ability neutralization activity Neutralizing antibodies neutralizing antibody neutralizing capacity Neutralizing titer neutralizing titers Phase 1 prefusion pseudovirus pseudoviruses RAT RATs reduced reduction reduction in respiratory retained S-2P SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants serum antibodies serum antibody serum sample serum samples severe acute respiratory syndrome Coronavirus significantly Spike protein subject subunit subunit SARS-CoV-2 vaccine the SARS-CoV-2 Vaccine Vaccines variant variant of concern variants VOCs wild-type [DOI] 10.1093/cid/ciab711 PMC 바로가기 [Article Type] Article
Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19COVID-19에 대한 비강내 예방으로서 광범위한 변이 활성을 갖는 계란 유래 항-SARS-CoV-2 면역글로불린 Y(IgY)Clinical Trial Published on 2022-06-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 2019 novel coronavirus 2019-nCoV activity Administered Against Alpha anti-SARS-CoV-2 Antiviral approval approvals B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta binding capture chicken immunoglobulin clinical clinical trial clinical trial body Clinical use contagiousness Convalescent patients COVID-19 cross-reactivity Delta demonstrated develop Diseases distribution double-blind effective Emergency use authorization enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Evidence evidence of greater healthy human tissue human tissues IgY Immunity immunized Immunoglobulin immunoglobulin Y index Infectious diseases intranasal intranasally multiple dose multiple doses nasal drop nasal drops nasal mucosa neutralization titer no evidence of Novel coronavirus omicron Phase 1 phase 1 study Placebo placebo-controlled Prevalence Prophylaxis raised Randomized RATs RBD Receptor-binding domain reduce reduced risk Safe safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral sensitivity sera Spike protein the receptor-binding domain the SARS-CoV-2 Tolerability Transmission Trial Vaccine Vaccine hesitancy variants variants of concern variety Viral virus [DOI] 10.3389/fimmu.2022.899617 PMC 바로가기 [Article Type] Clinical Trial
Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in ratsSARS-CoV-2 뉴클레오캡시드 단백질을 사용한 면역은 쥐에서 폐 면역 반응을 유발합니다Article Published on 2022-05-242022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] absence Activation administration affecting alteration animals anti-SARS-CoV-2 IgG antibodies anti-SARS-CoV-2 IgG antibody Asymptomatic biochemical can be used Clinical studies clinical study clinical symptom Clinical symptoms COVID-19 COVID-19 severity dead elicit emerging viruses Exacerbation groups histological histological analysis IgG antibodies immune response immunization immunological effect induce injection lead Local lung Microthrombosis multiple organ failure once a week Organ failure parameters produced Protein pulmonary immune response RATs Rattus Recombinant nucleocapsid protein recombinant proteins required Research respiratory insufficiency Safe SARS-CoV-2 SARS-CoV-2 pandemic sensitization Side effects Spread strain submitted Support synthesis Toxicity Trigger triggered vaccination Vaccine virus viruses world population [DOI] 10.1371/journal.pone.0268434 PMC 바로가기 [Article Type] Article
A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models자가 증폭 mRNA SARS-CoV-2 백신 후보는 전임상 모델에서 안전하고 강력한 보호 면역을 유도합니다Clinical Trial Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 임상, 진단, [키워드] (Alpha) (Beta Alpha animals Antigen B.1.1.7 B.1.351 B.1.617.2 Beta biodistribution breath CD4 CD8 T cell CD8 T cell responses characterized clinical evaluation Delta demonstrated disease dose-dependent manner Efficacy elicit elicited emergency response Evidence evidence of Frequency Germinal center hamsters humans immune responses immunization immunogenicity induce Lipid nanoparticle Lipid nanoparticles LNP lower airways Messenger RNA mice mRNA neutralized no evidence of Phase 1 Protective protective immune response protective immunity RATs reduced response RNA RNA vaccines robust Safe safety profile SAM SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants SARS-CoV-2 Wuhan strain self-amplifying mRNA Spike antigen spike-specific antibody response T cell the SARS-CoV-2 the vaccine Tolerance Toxicity upper and lower airways Vaccine vaccine candidate variants Viral Viral load Wuhan-Hu-1 [DOI] 10.1016/j.ymthe.2022.01.001 PMC 바로가기 [Article Type] Clinical Trial